-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Milestone Pharmaceuticals, Raises Price Target to $8

Benzinga·12/16/2025 15:02:33
语音播报
Wells Fargo analyst Mohit Bansal maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight and raises the price target from $4 to $8.